What is Wedbush’s Estimate for ORKA FY2029 Earnings?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) – Equities researchers at Wedbush issued their FY2029 EPS estimates for shares of Oruka Therapeutics in a research note issued to investors on Wednesday, May 14th. Wedbush analyst D. Nierengarten forecasts that the company will earn ($4.14) per share for the year. Wedbush currently has a “Outperform” rating and a $40.00 price target on the stock. The consensus estimate for Oruka Therapeutics’ current full-year earnings is ($3.41) per share.

ORKA has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research report on Friday, February 7th. Wolfe Research initiated coverage on shares of Oruka Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $20.00 price objective for the company. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $39.86.

Oruka Therapeutics Stock Up 6.3%

Shares of NASDAQ:ORKA opened at $10.06 on Friday. Oruka Therapeutics has a fifty-two week low of $5.49 and a fifty-two week high of $31.13. The firm has a 50-day simple moving average of $9.86 and a 200 day simple moving average of $14.77. The company has a market cap of $376.66 million, a PE ratio of -1.61 and a beta of 0.25.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.17.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. acquired a new position in Oruka Therapeutics during the 1st quarter valued at about $2,505,000. ADAR1 Capital Management LLC acquired a new stake in shares of Oruka Therapeutics in the 1st quarter worth approximately $1,362,000. Braidwell LP lifted its stake in shares of Oruka Therapeutics by 37.0% in the 1st quarter. Braidwell LP now owns 1,572,426 shares of the company’s stock worth $16,133,000 after acquiring an additional 424,750 shares during the period. OMERS ADMINISTRATION Corp lifted its stake in shares of Oruka Therapeutics by 126.8% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 44,900 shares of the company’s stock worth $461,000 after acquiring an additional 25,100 shares during the period. Finally, Affinity Asset Advisors LLC lifted its stake in shares of Oruka Therapeutics by 47.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 545,362 shares of the company’s stock worth $5,595,000 after acquiring an additional 176,664 shares during the period. 56.44% of the stock is owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.